CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) today reported results for the full year of 2024.

加利福尼亚州卡尔斯巴德，2025年3月24日（全球新闻通讯）——Acutus Medical, Inc.（“Acutus” 或 “公司”）今天公布了 2024 年全年的业绩。

Recent Highlights:

近期亮点：

2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.
Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.
Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.
Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024.

2024 年持续经营收入为 2020 万美元，同比增长 181%，去年为 720 万美元。
持续经营的营业亏损为 10 万美元，而去年为 1170 万美元。
记录了 1080 万美元的业务出售收益，比去年增长 19%。
截至2024年12月31日，现金、现金等价物、可交易证券和受限现金为 1400 万美元。

Full Year 2024 Financial Results

2024 年全年财务业绩

Revenue from Continuing Operations was $20.2 million for 2024, an increase of 181% compared to $7.2 million in 2023.

2024 年持续经营收入为 2020 万美元，比 2023 年的 720 万美元增长 181%。

Gross margin on a GAAP basis for continuing operations was 5% for 2024 compared to negative 44% for 2023. The improvement was driven by higher production volumes related to left-heart access manufacturing and reduced manufacturing overhead expenses.

2024 年持续经营的 GAAP 毛利率为 5%，而 2023 年为负 44%。这一改善得益于与左心通道制造相关的生产量增加和制造间接费用的减少。

Operating expenses for continuing operations on a GAAP basis was $1.1 million for 2024 compared to Operating expenses of $8.6 million last year. The decrease in operating expenses from reduced discretionary spend under this new business model.

2024 年持续经营的 GAAP 营业费用为 110 万美元，而去年为 860 万美元。营业费用的减少源于在这一新商业模式下减少的可自由支配支出。

Net loss on continuing operations on a GAAP basis was $4.6 million for 2024 and net loss per share was $0.16 on a weighted average basic and diluted outstanding share count of 29.8 million, compared to a net loss of $11.9 million and a net loss per share of $0.4 on a weighted average basic and diluted outstanding share count of 29.1 million for last year.

2024 年持续经营的 GAAP 净亏损为 460 万美元，按加权平均基本和稀释后流通股计，每股净亏损为 0.16 美元，而去年净亏损为 1190 万美元，每股净亏损为 0.4 美元，按加权平均基本和稀释后流通股计为 2910 万股。

Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024.

截至2024年12月31日，现金、现金等价物、可交易证券和受限现金为 1400 万美元。

Loss on Discontinued Operations

终止经营的亏损

Loss on discontinued operations was $5.0 million for 2024, compared to $69.7 million last year.

2024 年终止经营的亏损为 500 万美元，而去年为 6970 万美元。

Outlook

展望

Due to the announced plan to realign resources to support the left-heart access distribution business and exit from the electrophysiology mapping and ablation businesses, the Company will no longer provide financial guidance.

由于宣布计划重新调整资源以支持左心通道分销业务并退出电生理测绘和消融业务，公司将不再提供财务指导。

About Acutus

关于 Acutus

Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.

Acutus 专注于根据与美敦力公司（Medtronic, Inc.）的分销协议生产左心通道产品。Acutus 成立于 2011 年，总部位于加利福尼亚州卡尔斯巴德。

Caution Regarding Forward-Looking Statements

关于前瞻性声明的警告

This press release includes statements that may constitute “forward-looking” statements, usually containing the words 'believe", "estimate", "project", "expect" or similar expressions. Forward looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, successful completion of the Company’s restructuring plan, continued acceptance of the Company’s left-heart access products in the marketplace, the effect of global economic conditions on the ability and willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the Company’s ability to maintain its listing on Nasdaq, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

本新闻稿包含可能构成 “前瞻性” 声明的内容，通常包含 “相信”、“估计”、“项目”、“期望” 或类似表达。前瞻性声明固有地涉及风险和不确定性，可能导致实际结果与前瞻性声明存在重大差异。导致或促成此类差异的因素包括但不限于公司继续管理费用和现金消耗率的能力、公司重组计划的成功完成、公司左心通道产品在市场上的持续接受度、全球经济状况对美敦力购买公司左心通道产品的能力和意愿的影响及其购买时机、竞争因素、美国及全球医疗政策的变化，包括政府对程序的报销变化、对第三方供应商和分销商的依赖、监管批准的时机、公司维持在纳斯达克上市的能力，以及公司定期和其他向证券交易委员会提交的文件中讨论的其他风险。通过发布这些前瞻性声明，Acutus 不承担在本发布日期后因修订或变更而更新这些声明的义务，法律要求的除外。

Investor Contact:
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com

投资者联系：
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com


Acutus Medical, Inc.
Consolidated Balance Sheets

(in thousands, except share and per share amounts)	December 31,2024		December 31,2023
ASSETS
Current assets:
Cash and cash equivalents	$	14,019		$	19,170
Marketable securities, short-term		—			3,233
Restricted cash, short-term		—			7,030
Accounts receivable		7,878			11,353
Inventory		1,790			4,278
Prepaid expenses and other current assets		641			678
Current assets of discontinued operations (Note 3)		1,250			510
Total current assets		25,578			46,252

Property and equipment, net		517			825
Right-of-use assets, net		2,459			3,189
Other assets		94			94
Non-current assets of discontinued operations (Note 3)		—			3,600
Total assets	$	28,648		$	53,960

LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable		1,276			2,761
Accrued liabilities		3,006			2,887
Operating lease liabilities, short-term		957			718
Long-term debt, current portion		7,005			1,864
Warrant liability		194			409
Current liabilities of discontinued operations (Note 3)		—			10,303
Total current liabilities		12,438			18,942

Operating lease liabilities, long-term		2,238			3,243
Long-term debt		25,564			32,654
Total liabilities		40,240			54,839

Commitments and contingencies (Note 12)

Stockholders' (deficit) equity

Preferred stock, $0.001 par value; 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		—			—
Common stock, $0.001 par value; 260,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 29,912,305 and 29,313,667 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		30			29
Additional paid-in capital		598,670			599,935
Accumulated deficit		(609,524	)		(599,977	)
Accumulated other comprehensive loss		(768	)		(866	)
Total stockholders' deficit		(11,592	)		(879	)
Total liabilities and stockholders' deficit	$	28,648		$	53,960


药明康德， Inc.
合并资产负债表

（以千为单位，除每股和每股金额外）	2024年12月31日		2023年12月31日
资产
流动资产：
现金及现金等价物	$	14,019		$	19,170
短期可交易证券		—			3,233
短期受限现金		—			7,030
应收账款		7,878			11,353
存货		1,790			4,278
预付费用及其他流动资产		641			678
停业业务的流动资产（注 3）		1,250			510
流动资产总计		25,578			46,252

净物业及设备		517			825
净使用权资产		2,459			3,189
其他资产		94			94
停业业务的非流动资产（注 3）		—			3,600
资产总计	$	28,648		$	53,960

负债及股东（亏损）权益
流动负债：
应付账款		1,276			2,761
应计负债		3,006			2,887
短期经营租赁负债		957			718
长期债务，当前部分		7,005			1,864
权证负债		194			409
停业业务的流动负债（注 3）		—			10,303
流动负债总计		12,438			18,942

长期经营租赁负债		2,238			3,243
长期债务		25,564			32,654
负债总计		40,240			54,839

承诺和或有事项（注 12）

股东（亏损）权益

优先股，面值$0.001；截至2024年12月31日和2023年12月31日授权 5,000,000 股；截至2024年12月31日和2023年12月31日，已发行并流通的优先股为 6,666 股，指定为 A 系列普通等值优先股		—			—
普通股，面值$0.001；截至2024年12月31日和2023年12月31日授权 260,000,000 股；截至2024年12月31日和2023年12月31日，已发行并流通的普通股为 29,912,305 股和 29,313,667 股		30			29
额外实收资本		598,670			599,935
累计亏损		(609,524	)		(599,977	)
累计其他综合损失		(768	)		(866	)
股东亏损总计		(11,592	)		(879	)
负债和股东亏损总计	$	28,648		$	53,960


Acutus Medical, Inc.
Consolidated Statements of Operations and Comprehensive Loss

	Year Ended December 31,
(in thousands, except share and per share amounts)	2024		2023
Revenue	$	20,157		$	7,164
Cost of products sold		19,144			10,301
Gross profit (loss)		1,013			(3,137	)

Operating expenses (income):
Research and development		—			3,482
Selling, general and administrative		10,436			14,066
Restructuring		1,448			—
Change in fair value of contingent consideration		—			123
Gain on sale of business		(10,814	)		(9,080	)
Total operating expenses		1,070			8,591
Loss from operations		(57	)		(11,728	)

Other income (expense):
Change in fair value of warrant liability		215			2,937
Interest income		763			2,588
Interest expense		(5,758	)		(5,655	)
Other revenue		301			—
Total other expense, net		(4,479	)		(130	)
Loss from continuing operations before income taxes		(4,536	)		(11,858	)
Income tax (benefit) expense		—			63
Net loss from continuing operations		(4,536	)		(11,921	)
Discontinued operations:
Loss from discontinued operations before income taxes		(4,999	)		(69,530	)
Income tax expense - discontinued operations		12			212
Loss from discontinued operations		(5,011	)		(69,742	)
Net loss	$	(9,547	)	$	(81,663	)

Other comprehensive income (loss):
Unrealized gain on marketable securities		—			7
Foreign currency translation adjustment		98			(4	)
Comprehensive loss	$	(9,449	)	$	(81,660	)

Net loss per share, basic and diluted:
Loss from continuing operations	$	(0.15	)	$	(0.41	)
Loss from discontinued operations	$	(0.17	)	$	(2.40	)
Net loss per common share, basic	$	(0.32	)	$	(2.81	)

Weighted average number of common shares outstanding, basic and diluted		29,768,208			29,095,294


药明康德， Inc.
合并运营和综合损失报表

	截至 12 月 31 日的年度
（以千为单位，除每股和每股金额外）	2024		2023
收入	$	20,157		$	7,164
销售产品成本		19,144			10,301
毛利润（损失）		1,013			(3,137	)

运营费用（收入）：
研发费用		—			3,482
销售、一般和行政费用		10,436			14,066
重组费用		1,448			—
有条件对价公允价值变动		—			123
业务出售收益		(10,814	)		(9,080	)
运营费用总计		1,070			8,591
运营损失		(57	)		(11,728	)

其他收入（费用）：
权证负债公允价值变动		215			2,937
利息收入		763			2,588
利息费用		(5,758	)		(5,655	)
其他收入		301			—
其他费用净额		(4,479	)		(130	)
持续运营的损失（所得税前）		(4,536	)		(11,858	)
所得税（收益）费用		—			63
持续运营的净损失		(4,536	)		(11,921	)
停业业务：
停业业务的损失（所得税前）		(4,999	)		(69,530	)
停业业务的所得税费用		12			212
停业业务的净损失		(5,011	)		(69,742	)
净损失	$	(9,547	)	$	(81,663	)

其他综合收入（损失）：
短期可交易证券未实现收益		—			7
外币换算调整		98			(4	)
综合损失	$	(9,449	)	$	(81,660	)

每股净损失，基本和稀释后：
持续运营的损失	$	(0.15	)	$	(0.41	)
停业业务的损失	$	(0.17	)	$	(2.40	)
每普通股净损失，基本	$	(0.32	)	$	(2.81	)

基本和稀释后普通股加权平均流通股数		29,768,208			29,095,294


Acutus Medical, Inc.
Consolidated Statements of Cash Flows


(in thousands)	2024		2023
Cash flows from operating activities
Net loss	$	(9,547	)	$	(81,663	)
Less: Loss on discontinued operations		5,011			69,742
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		297			191
Non-cash stock-based compensation expense		459			3,032
Accretion of discounts on marketable securities, net		(28	)		(1,428	)
Amortization of debt issuance costs		931			571
Amortization of operating lease right-of-use assets		730			683
Gain on sale of business, net		(10,814	)		(9,080	)
Change in fair value of warrant liability		(215	)		(2,937	)
Change in fair value of contingent consideration		—			123
Changes in operating assets and liabilities:
Accounts receivable		(4,048	)		(1,074	)
Inventory		2,488			(2,484	)
Employer retention credit receivable		—			4,703
Prepaid expenses and other current assets		48			656
Accounts payable		(1,485	)		288
Accrued liabilities		(246	)		(700	)
Operating lease liabilities		(766	)		(461	)
Other long-term liabilities		—			(12	)
Net cash used in operating activities - continuing operations		(17,185	)		(19,850	)
Net cash used in operating activities - discontinued operations		(14,475	)		(43,268	)
Net cash used in operating activities		(31,660	)		(63,118	)

Cash flows from investing activities
Proceeds from sale of business		18,672			17,000
Purchases of available-for-sale marketable securities		—			(39,765	)
Sales of available-for-sale marketable securities		500			750
Maturities of available-for-sale marketable securities		2,750			82,000
Purchases of property and equipment		(112	)		(219	)
Net cash provided by investing activities - continuing operations		21,810			59,766
Net cash provided by (used in) investing activities - discontinued operations		339			(1,211	)
Net cash provided by investing activities		22,149			58,555

Cash flows from financing activities
Repayment of debt		(2,625	)		—
Payment of debt issuance costs		—			(490	)
Proceeds from the exercise of stock options		—			4
Proceeds from employee stock purchase plan		—			25
Payment of contingent consideration		—			(1,923	)
Net cash used in financing activities - continuing operations		(2,850	)		(2,384	)
Net cash used in financing activities - discontinued operations		(41	)		(280	)
Net cash used in financing activities		(2,891	)		(2,664	)

Effect of exchange rate changes on cash, cash equivalents and restricted cash		221			2,079

Net change in cash, cash equivalents and restricted cash		(12,181	)		(5,148	)
Cash, cash equivalents and restricted cash, at the beginning of the period		26,200			31,348
Cash, cash equivalents and restricted cash, at the end of the period	$	14,019		$	26,200

Supplemental disclosure of cash flow information:
Cash paid for interest	$	4,544		$	5,012

Supplemental disclosure of noncash investing and financing activities:
Changes between assets and liabilities in discontinued operations	$	—		$	5,445
Accounts receivable from sale of business	$	1,838		$	9,360
Change in unrealized (gain) loss on marketable securities	$	—		$	(7	)


Acutus Medical, Inc.
合并现金流量表


(单位：千美元)	2024		2023
来自经营活动的现金流
净亏损	$	(9,547	)	$	(81,663	)
减：终止经营损失		5,011			69,742
调整净亏损以对账用于经营活动的净现金：
折旧费用		297			191
非现金股票补偿费用		459			3,032
可交易证券折扣的增值，净额		(28	)		(1,428	)
债务发行成本的摊销		931			571
租赁使用权资产的摊销		730			683
业务出售收益，净额		(10,814	)		(9,080	)
权证负债公允价值变动		(215	)		(2,937	)
有条件对价公允价值变动		—			123
经营资产和负债的变动：
应收账款		(4,048	)		(1,074	)
存货		2,488			(2,484	)
雇主保留税收抵免应收款		—			4,703
预付费用及其他流动资产		48			656
应付账款		(1,485	)		288
应计负债		(246	)		(700	)
租赁负债		(766	)		(461	)
其他长期负债		—			(12	)
来自经营活动的净现金 - 持续经营		(17,185	)		(19,850	)
来自经营活动的净现金 - 终止经营		(14,475	)		(43,268	)
来自经营活动的净现金		(31,660	)		(63,118	)

来自投资活动的现金流
业务出售收益		18,672			17,000
购买可供出售的可交易证券		—			(39,765	)
出售可供出售的可交易证券		500			750
可供出售的可交易证券到期		2,750			82,000
购买物业和设备		(112	)		(219	)
来自投资活动的净现金 - 持续经营		21,810			59,766
来自投资活动的净现金（使用）- 终止经营		339			(1,211	)
来自投资活动的净现金		22,149			58,555

来自融资活动的现金流
偿还债务		(2,625	)		—
支付债务发行成本		—			(490	)
行使股票期权的收益		—			4
员工股票购买计划的收益		—			25
支付有条件对价		—			(1,923	)
来自融资活动的净现金 - 持续经营		(2,850	)		(2,384	)
来自融资活动的净现金 - 终止经营		(41	)		(280	)
来自融资活动的净现金		(2,891	)		(2,664	)

汇率变动对现金、现金等价物和受限现金的影响		221			2,079

现金、现金等价物和受限现金的净变动		(12,181	)		(5,148	)
期初现金、现金等价物和受限现金		26,200			31,348
期末现金、现金等价物和受限现金	$	14,019		$	26,200

现金流信息的补充披露：
支付的利息	$	4,544		$	5,012

非现金投资和融资活动的补充披露：
终止经营中资产与负债的变动	$	—		$	5,445
业务出售的应收账款	$	1,838		$	9,360
可交易证券未实现（收益）损失的变动	$	—		$	(7	)

Acutus Medical 公布 2024 年全年财务业绩